Radius Health
Radius Health is a biopharmaceutical company that developed abaloparatide, the bone-building drug the FDA approved as Tymlos in 2017 to reduce fractures in postmenopausal women with osteoporosis.
President and CEO
Robert Ward
Key facts
- Company
- Science-driven biopharmaceutical company based in Waltham, Massachusetts (Nasdaq: RDUS), focused on osteoporosis, oncology and endocrine diseasessource
- Drug
- Developed abaloparatide, approved by the FDA as Tymlos on April 28, 2017source
- First in class
- Tymlos was the first new anabolic bone-building agent for postmenopausal women with osteoporosis in the United States in nearly 15 yearssource
WYDE coverage of Radius Health
Sources
Track the institutions that move money.
Data-driven coverage every Friday.